Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 5mg | $44.99 | $9.00/mg | In stock | Jul 8 |
| vial | 10mg | $89.99 | $9.00/mg | In stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| OR-LPTES5-526-B6 | May 2026 | 99.0% | Ethos Analytics | Endotoxin, Heavy metals | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. Tesamorelin is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does OROS Research sell Tesamorelin?
Yes — OROS Research currently lists Tesamorelin in 2 variants starting at $44.99 ($9.00/mg).
Is OROS Research's Tesamorelin third-party tested?
Yes — Disclosed Labs has indexed 2 Certificates of Analysis for OROS Research's Tesamorelin, with the most recent showing 99.0% purity. OROS Research holds an overall trust grade of A (92/100) across all 44 COAs on file.
What is OROS Research's trust grade for Tesamorelin?
OROS Research has an overall Disclosed Labs trust grade of A (92/100), computed from 44 COAs across all peptides. The most recent Tesamorelin COA was issued by Ethos Analytics.
Where is the cheapest Tesamorelin?
As of the latest data, Peptide Supply Co. offers Tesamorelin at $3.50/mg — compare with OROS Research's listing at $9.00/mg. See the full Tesamorelin price comparison.
Is Tesamorelin legal to buy?
Tesamorelin is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| OR-LPTES5-326-B5 | Apr 2026 | 99.0% | Ethos Analytics | Endotoxin, Heavy metals | Confirmed | View |
Disclosed Labs